(Q35162373)

English

Epidermal growth factor receptor (EGFR) as a target in cancer therapy: understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12826036%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

1 reference

Europe PubMed Central

Epidermal growth factor receptor (EGFR) as a target in cancer therapy: understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12826036%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

Fortunato Ciardiello

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12826036%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

Giampaolo Tortora

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12826036%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

author name string

F Ciardiello

1

1 reference

Europe PubMed Central

6 August 2017

Giampaolo Tortora

2

1 reference

Europe PubMed Central

6 August 2017

publication date

1 July 2003

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12826036%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

European Journal of Cancer

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12826036%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

39

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12826036%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

1348-1354

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12826036%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12826036%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

Epidermal growth factor receptor tyrosine kinase inhibitors as anticancer agents

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900235-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Epidermal growth factor-related peptides and their receptors in human malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900235-1

7 January 2021

based on heuristic

inferred from DOI database lookup

The epidermal growth factor receptor and its inhibition in cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900235-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Untangling the ErbB signalling network

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900235-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Monoclonal antibodies directed at growth factor receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900235-1

7 January 2021

based on heuristic

inferred from DOI database lookup

ZD1839 ('Iressa') as an anticancer agent

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900235-1

7 January 2021

based on heuristic

inferred from DOI database lookup

ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900235-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900235-1

7 January 2021

based on heuristic

inferred from DOI database lookup

EGFR and cancer prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900235-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900235-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic value of ERBB-1, VEGF, cyclin A, FOS, JUN and MYC in patients with squamous cell lung carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900235-1

7 January 2021

based on heuristic

inferred from DOI database lookup

The relationship of epidermal growth factor receptor levels to the prognosis of unresectable pharyngeal cancer patients treated by chemo-radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900235-1

7 January 2021

based on heuristic

inferred from DOI database lookup

The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900235-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Constitutive activation of phosphatidylinositol 3-kinase by a naturally occurring mutant epidermal growth factor receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900235-1

7 January 2021

based on heuristic

inferred from DOI database lookup

EGF-related peptides in the pathophysiology of the mammary gland

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900235-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Co-expression of epidermal growth factor receptor and transforming growth factor-alpha predicts worse prognosis in breast-cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900235-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900235-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Tyrosine kinase signalling in breast cancer. Epidermal growth factor receptor: convergence point for signal integration and diversification

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900235-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Employment of the epidermal growth factor receptor in growth factor-independent signaling pathways

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900235-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Expression of transforming growth factor alpha and its messenger ribonucleic acid in human breast cancer: its regulation by estrogen and its possible functional significance

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900235-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900235-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900235-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900235-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900235-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Antitumor Activity of Combined Blockade of Epidermal Growth Factor Receptor and Protein Kinase A

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900235-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Cooperative inhibition of renal cancer growth by anti-epidermal growth factor receptor antibody and protein kinase A antisense oligonucleotide.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900235-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0959-8049(03)00235-1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12826036%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12826036%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35162373&oldid=1527102462"